News | Magnetic Resonance Imaging (MRI) | December 29, 2015

Novel MRI Imaging Agent More Effectively Monitors Impact of Treatment in Lung, Prostate Cancers

Novel MRI Imaging Agent More Effectively Monitors Impact of Treatment in Lung, Prostate Cancers

Molecular imaging of the GRPR biomarker on mice xenografted with PC3 and H441 cells by T1-weighted spin echo MR imaging and NIR imaging.

December 29, 2015 — A method to better trace changes in cancers and treatment of the prostate and lung without the limitations associated with radiation has been developed with a new magnetic resonance imaging (MRI) imaging agent (Scientific Reports. doi:10.1038/srep16214).

The researchers developed a new imaging agent they named ProCA1.GRPR, and demonstrated that it leads to strong tumor penetration and is capable of targeting the gastrin-releasing peptide receptor expressed on the surface of diseased cells, including prostate, cervical and lung cancer cells.

Molecular imaging of cancer predictors using MRI offers better and improved understanding of various cancers and drug activity during preclinical and clinical treatments. However, one of the major barriers in using MRI in evaluating specific disease predictors for diagnosis and monitoring drug effects is the lack of highly sensitive and specific imaging agents capable of showing the difference between normal tissue and tumors.

"ProCA1.GRPR has a strong clinical translation for human application and represents a major step forward in the quantitative imaging of disease biomarkers without the use of radiation," said lead author Jenny J. Yang, Ph.D., professor and associate director of the Center for Diagnostics and Therapeutics at Georgia State University in Atlanta. "This information is valuable for staging disease progression and monitoring treatment effects."

The researchers' results are an important advancement for molecular imaging. This agent has a unique ability to quantitatively detect expression level and spatial distribution of disease predictors without using radiation.

"Our discovery is of great interest to both chemists and clinicians for disease diagnosis, including noninvasive early detection of human diseases, cancer biology, molecular basis of human diseases, and translational research with preclinical and clinical applications," said coauthor Shenghui Xue, Ph.D., postdoctoral researcher in Georgia State Department of Chemistry.

Improved imaging agents such as ProCA1.GRPR have implications in understanding disease development and treatment.

For more information: www.nature.com/articles/srep16214

Related Content

The Revolution Apex intelligent computed tomography (CT) scanner

The Revolution Apex intelligent computed tomography (CT) scanner. Image courtesy of GE Healthcare.

News | RSNA | October 18, 2019
At the 2019 annual meeting of the Radiological Society of North America (RSNA 2019), Dec. 1-6 in Chicago, GE Healthcare...
Guerbet Signs Agreement With Icometrix for Exclusive Distribution of Icobrain
News | Neuro Imaging | October 16, 2019
Guerbet announced it has signed an exclusive agreement with Icometrix for the distribution in France, Italy and Brazil...
Subtle Medical Receives FDA 510(k) Clearance for AI-powered SubtleMR
Technology | Artificial Intelligence | October 16, 2019
Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SubtleMR. SubtleMR...
Using Compressed SENSE for faster MRI scans, healthcare providers can transform their radiology workflow.

Using Compressed SENSE for faster MRI scans, healthcare providers can transform their radiology workflow.

Sponsored Content | Case Study | Magnetic Resonance Imaging (MRI) | October 16, 2019
Since the introduction of magnetic resonan...
Canon Medical Receives FDA Clearance for Vantage Orian 1.5T MRI

Canon Medical Receives FDA Clearance for Vantage Orian 1.5T MRI

Feature | Magnetic Resonance Imaging (MRI) | October 09, 2019 | By Jeff Zagoudis
Patient Treatments With ViewRay's MRIdian Linac Begin in New England
News | Image Guided Radiation Therapy (IGRT) | October 08, 2019
ViewRay Inc. announced today that patient treatments are scheduled to begin in Boston with ViewRay's MRIdian Linac...
Machine Learning Could Offer Faster, More Precise Cardiac MRI Scan Results
News | Magnetic Resonance Imaging (MRI) | September 25, 2019
Cardiac magnetic resonance imaging (MRI) analysis can be performed significantly faster with similar precision to...
Colorado Orthopedic Clinic Adds Canon Medical Vantage Galan 3T MRI to Frisco Clinic Location
News | Magnetic Resonance Imaging (MRI) | September 25, 2019
The Steadman Clinic has added Canon Medical Systems USA Inc.’s Vantage Galan 3T magnetic resonance (MR) system to the...
Bayer Introduces Medrad Stellant Flex CT Injection System
Technology | Contrast Media Injectors | September 11, 2019
Bayer announced the introduction of the Medrad Stellant Flex computed tomography (CT) injection system. Stellant Flex...
Imaging Biometrics and Medical College of Wisconsin Awarded NIH Grant
News | Neuro Imaging | September 09, 2019
Imaging Biometrics LLC (IB), in collaboration with the Medical College of Wisconsin (MCW), has received a $2.75 million...